Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants.

[1]  E. Roughead,et al.  Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study , 2019, BMJ Open.

[2]  A. Farcomeni,et al.  Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. , 2018, European journal of internal medicine.

[3]  T. Gerds,et al.  Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.

[4]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[5]  D. Singer,et al.  Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice , 2017, Annals of Internal Medicine.

[6]  A. Farcomeni,et al.  Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[7]  P. Souverein,et al.  Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants , 2017, British journal of clinical pharmacology.

[8]  F. Violi,et al.  Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. , 2016, Pharmacological research.

[9]  L. Fauchier,et al.  Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists , 2016, Thrombosis and Haemostasis.

[10]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[11]  E. Soliman,et al.  Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms , 2016, Journal of the American Heart Association.

[12]  A. Farcomeni,et al.  Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. , 2015, Chest.

[13]  V. Howard,et al.  Atrial fibrillation and the risk of myocardial infarction. , 2015, JAMA internal medicine.

[14]  F. Violi,et al.  Myocardial infarction and atrial fibrillation: different impact of anti-IIa vs anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials. , 2015, International journal of cardiology.

[15]  G. Breithardt,et al.  Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial , 2014, Journal of the American Heart Association.

[16]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[17]  R. de Caterina,et al.  Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation , 2013, Circulation.

[18]  G. Lip,et al.  Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis , 2012, BMJ : British Medical Journal.

[19]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[20]  Adrian V. Hernández,et al.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.

[21]  G. Grigoriadis,et al.  Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. , 2011, Blood.

[22]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[23]  G. Lip,et al.  Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? , 2010, American Journal of Medicine.

[24]  G. Lip,et al.  Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis , 2017, Stroke.